GlassScriptPhysician profile
Laini Rae Gaar
NPI 1700029337
$38,438.99
in general payments reported to CMS, 2019-2025
34 companies · $11K in 2025
The $11K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,602 · 2020: $1,099 · 2021: $1,924 · 2022: $2,025 · 2023: $7,444 · 2024: $13K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $8,084 · Consulting Fee: $4,750 · Travel and Lodging: $2,235 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,343.00 |
| Food and Beverage | $8,084.48 |
| Consulting Fee | $4,750.00 |
| Travel and Lodging | $2,234.67 |
| Education | $376.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20,562.06 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $9,128.13 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,493.38 | 2019-2025 | Ilumya, Blu-U |
| Novartis Pharmaceuticals Corporation | $1,337.03 | 2019-2025 | |
| Lilly USA, LLC | $995.34 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $848.31 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $580.99 | 2021-2025 | |
| Pfizer INC. | $517.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $435.31 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $300.61 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $300.40 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $281.83 | 2019-2023 | Siliq |
| Amgen INC. | $273.46 | 2020-2024 | Otezla |
| Celgene Corporation | $235.29 | 2019 | |
| Leo Pharma INC. | $192.71 | 2020-2025 | Adbry, Spevigo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.40 | 2024-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $150.13 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $133.29 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Almirall LLC | $62.23 | 2022-2025 | Seysara, Klisyri |
| Dermavant Sciences, INC. | $61.93 | 2023-2024 | Vtama |
| Incyte Corporation | $53.16 | 2022-2023 | Opzelura |
| Dusa Pharmaceuticals, INC. | $28.11 | 2019 | |
| Merck Sharp & Dohme LLC | $26.85 | 2019 | |
| Organon LLC | $26.75 | 2025 | Vtama |
| Kyowa Kirin, INC. | $25.97 | 2024 | Poteligeo |
| Biofrontera INC. | $22.35 | 2025 | Ameluz |
| Sandoz INC. | $20.32 | 2020 | |
| Verrica Pharmaceuticals INC. | $19.96 | 2024 | Ycanth |
| Allergan, INC. | $18.94 | 2019 | |
| Merz North America, INC. | $17.17 | 2021 | |
| Genentech USA, INC. | $16.76 | 2021 | |
| Strata Skin Sciences, INC. | $13.83 | 2024 | Xtrac |
| Kerecis Limited | $10.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laini Gaar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.